WU, a 10-year-old boy from Korea, was born with a large congenital skin lesion that gradually transformed into melanoma as he grew older. The disease progressed rapidly, and within a short period, the tumor enlarged significantly and was accompanied by serious complications that disrupted daily life. Genetic testing revealed an NRAS Q61H mutation. Multiple treatments—including immunotherapy, immune-combination regimens, and targeted therapy—had been attempted but failed to control the disease. The mass continued to grow, and extensive pleural effusion developed, severely affecting his quality of life.

At this critical point, WU’s mother reached out to the team of Professor Jun Guo at GoBroad Healthcare Group, hoping to find a new treatment opportunity for her child. After evaluating his weight, tolerance, and overall condition, Professor Guo’s team designed a personalized pediatric plan: Tunlametinib at half the standard adult dose combined with immunotherapy, aiming to maintain adequate NRAS-MEK pathway inhibition while ensuring safety for a young patient.

Within just four weeks of treatment, WU experienced noticeable improvement. The previously prominent axillary mass began to shrink, associated symptoms relieved markedly, and the concerning pleural effusion resolved. Follow-up imaging confirmed the positive changes, with no new lesions detected. The overall treatment course was gentle and well-tolerated, enabling the child to continue therapy with greater ease.

For a pediatric patient facing rapid disease progression after multiple unsuccessful treatments, this swift response was profoundly meaningful. It brought renewed hope to his family. The clinical team also observed that the half-dose regimen demonstrated both strong activity and favorable safety in NRAS-mutant pediatric melanoma, offering valuable insights for future dose-optimization studies in children.